Investor Relations

Advanced therapies for the sports medicine and severe burn care markets

Day High:
Day Low:
Volume:
on
Data Provided by Refinitiv. Minimum 15 minutes delayed.

Investor Relations

Press Releases

May 7, 2026

Vericel Reports First Quarter 2026 Financial Results and Raises Full-Year Financial Guidance

April 23, 2026

Vericel to Report First-Quarter 2026 Financial Results on May 7, 2026

April 2, 2026

Vericel Announces BARDA Award Valued at up to $197 Million for Procurement and Advanced Development of NexoBrid

Events and Presentations

Upcoming Events
More events are coming soon.

 

 

Presentations

Stock Quote & Analyst Coverage

Stock Quote ()

Change
Volume
Today's Open
Previous Close
Today's High
Today's Low
52 Week High
52 Week Low
Vericel Corporation is covered by the following analysts.
Ryan Zimmerman
BTIG
Caitlin Cronin
Canaccord Genuity
Swayampakula Ramakanth
H.C. Wainwright & Co.
Jeff Cohen
Ladenburg Thalmann
Mike Kratky
Leerink
Mason Carrico
Stephens
Joshua Jennings, MD
TD Cowen
Richard Newitter
Truist

Vericel Corporation is followed by the analysts listed. Please note that any opinions, estimates or forecasts regarding Vericel Corporation's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Vericel Corporation or its management. Vericel Corporation does not by its reference or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.